&nbsp;

Kirsten-Burgomaster.png

Jun 2019

Document

Kirsten-Burgomaster---BW.jpg

Jun 2019

Document

Kirsten-Burgomaster---BW2.jpg

Jun 2019

Statistical Reports

Key Findings

Document

XELOX.pdf

Jun 2020

Document

XELOX-FR.pdf

Jun 2020

Regimen

XELOX+TRAS

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) - Advanced Gastric, Gastroesophageal, or Esophageal Cancer

ODB - General Benefit

capecitabine

Drugs Used:

Quick Link(s):

Regimen Monograph

Sep 2023

Regimen

XELOX+NIVL

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab - First-line Treatment of Advanced Gastric, Esophageal, and Esophagogastric Junction Adenocarcinoma

ODB - General Benefit

capecitabine

Drugs Used:

Quick Link(s):

Regimen Monograph

Apr 2023

Regimen

XELOX+BEVA

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

ODB - General Benefit

capecitabine

New Drug Funding Program

Bevacizumab (Biosimilar) - Metastatic Colorectal, Small Bowel, or Appendiceal Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

XELOX

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

ODB - General Benefit

capecitabine

Drugs Used:

oxaliplatin,

capecitabine

... Show more tags

Quick Link(s):

Regimen Monograph, Patient Info Sheet (XELOX)

Jan 2024

Statistical Reports

Key Findings [2022]

Document